InMed board director Catherine Sazdanoff resigns; Janet Grove appointed as replacement

InMed Pharmaceuticals Inc.

Catherine Sazdanoff resigned from Board effective Feb 11, 2022 due to personal reasons.
Janet Grove appointed as director effective Feb 11, 2022 to fill vacancy; term expires at 2022 AGM.
Grove to serve on Compensation and Nominating & Governance Committees.
Grove receives $35K annual retainer, up to $15K for committee service, plus stock options for 14,000 shares.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Catherine Sazdanoff

Director

INM · InMed Pharmaceuticals Inc.

Effective: 2022-02-11
Successor: Janet Grove
Filed: February 23, 2022, 6:59 PM ET

On February 11, 2022, Catherine Sazdanoff resigned from the Board of Directors (the “Board”) (including from the Compensation Committee, the Nominating & Governance Committee and the Audit Committee) of InMed Pharmaceuticals Inc. (the “Company”), effective as of February 11,2022.

Appointed

Janet Grove

Director

INM · InMed Pharmaceuticals Inc.

Effective: 2022-02-11
Filed: February 23, 2022, 6:59 PM ET

On February 11, 2022, the Board appointed Janet Grove as a director of the Board to fill the vacancy created by Ms. Sazdanoff’s resignation, effective as of February 11, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Catherine Sazdanoff resigned as Director at InMed Pharmaceuticals Inc..

Action: resigned
Role: Director

Exact text from the filing

On February 11, 2022, Catherine Sazdanoff resigned from the Board of Directors (the “Board”) (including from the Compensation Committee, the Nominating & Governance Committee and the Audit Committee) of InMed Pharmaceuticals Inc. (the “Company”), effective as of February 11,2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Janet Grove was appointed as Director at InMed Pharmaceuticals Inc..

Action: appointed
Role: Director

Exact text from the filing

On February 11, 2022, the Board appointed Janet Grove as a director of the Board to fill the vacancy created by Ms. Sazdanoff’s resignation, effective as of February 11, 2022.

View on SEC.gov

InMed Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-008887

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.